Eder, C. and Wild, C. (2019): Advanced Therapy Medicinal Products (ATMPs): Technology forecast. Journal of Market Access & Health Policy 7 (1).
Full text not available from this repository.
"Advanced Therapy Medicinal Products" (ATMPs) is the umbrella term for three classes of medicinal products: somatic cell therapy medicinal products, gene therapy medicinal products and biotechnologically processed tissue preparations [also known as tissue engineering products (TEP)], as well as combination products. These drugs contain -or mostly consist of- living cells or tissues and are therefore highly complex. The cells used are often taken from a patient, processed in the laboratory (e.g. increased or genetically modified) and then administered again to the same patient.
The review of the LBI-HTA (published only as an English publication, not as a report) gives an overview of applications of ATMP products shortly before or after their market launch.
|Keywords:||ATMP, Advanced Therapy Medicinal Products, Cell therapy, Tissue Engineering, gene therapy|
|Subjects:||WB Practice of medicine > WB 300-962 Therapeutics|
QT Physiology > QT 34-37 Physics. Mathematics. Engineering > QT 36-37 Biomedical engineering, nanotechnology, biocompatible materials
QU Biochemistry > QU 300-375 Cells
|Deposited on:||29 Apr 2019 12:09|
|Last Modified:||02 May 2019 12:39|
Repository Staff Only: item control page